Tevogen Inc.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy company developing off-the-shelf, allogeneic T cell therapies for infectious diseases, cancers and other disorders. Its ExacTcell technology selects and expands naturally occurring, genetically unmodified CD8+ cytotoxic T cells that… From the company’s description.
In fiscal 2025, Tevogen Inc. reported a net loss of $26.28M. Operations used $12.33M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tevogen Inc. does
In the company’s own words
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy company developing off-the-shelf, allogeneic T cell therapies for infectious diseases, cancers and other disorders. Its ExacTcell technology selects and expands naturally occurring, genetically unmodified CD8+ cytotoxic T cells that target multiple defined antigens on infected or malignant cells. The lead candidate, TVGN 489, is being developed to treat COVID-19 in immunocompromised and other high-risk patients and for potential treatment and prevention of Long COVID; the company has completed a Phase 1 trial and plans further clinical development. Tevogen is also building a pipeline of therapies for additional viral and cancer indications. Its products are designed for patients whose HLA type matches the therapy, with the aim of enabling premanufactured doses for multiple patients from a single donor. The company’s principal asset is its ExacTcell platform, and it has no products approved for commercial sale or product-sales revenue. Its website is https://tevogen.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WARREN, NJ
- Fiscal year end
- December
- CIK
- 1860871
- SIC
- 2836
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tevogen Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tevogen Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tevogen Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tevogen Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tevogen Inc.'s last four quarterly filings that the numbers alone won't show?”